Results 191 to 200 of about 285,740 (285)

Using large language models for enhanced fraud analysis and detection in blockchain based health insurance claims. [PDF]

Sci Rep
Islayem R, Gebreab S, AlKhader W, Musamih A, Salah K, Jayaraman R, Khan MK.   +6 more
europepmc   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Medicolegal litigation in general surgery: a comparison between England and the United States. [PDF]

Health Res Policy Syst
Nebo V, Fadel MG, Poynter L, Ashrafian H, Bailey C, Fehervari M.   +5 more
europepmc   +1 more source

Activity Report of the Liaison Meetings of Reserchers Interested in Health Insurance Claims as Data Source

Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku, 1998
openaire   +2 more sources

The Computerization of Mass Tort Settlement Facilities [PDF]

, 1990
Florence, B. Thomas, Gurney, Judith
core   +1 more source

Underrepresentation of Black Individuals in Basal Cell and Squamous Cell Carcinoma Clinical Trials: A Comparison to an Insurance Claimant Cohort

JEADV Clinical Practice, EarlyView.
Black patients are significantly underrepresented in skin cancer clinical trials, with 85% and 66% of Black patients with basal cell and squamous cell carcinoma, respectively, unrepresented in trials. This limits the generalizability of trial results to Black patients, further exacerbating health inequity.
Mara Hartoyo, Natalie Goulett, Olivia Burke, Alyx Rosen Aigen   +3 more
wiley   +1 more source

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkish Oncology Centers. [PDF]

Med Sci Monit
Güzel HG, Önder AH, İlhan Y, Balçık OY, Öztürk B.   +4 more
europepmc   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma. [PDF]

J Health Econ Outcomes Res
Dennen S, Masek M, Cockrum P, Nagelhout E, Paluri R.   +4 more
europepmc   +1 more source

Erratum to “Validity Assessment of Self-reported Medication Use for Hypertension, Diabetes, and Dyslipidemia in a Pharmacoepidemiologic Study by Comparison With Health Insurance Claims”

, 2021
Matsumoto, Minako, Harada, Sei, Iida, Miho, Kato, Suzuka, Sata, Mizuki, Hirata, Aya, Kuwabara, Kazuyo, Takeuchi, Ayano, Sugiyama, Daisuke, Okamura, Tomonori, Takebayashi, Toru   +10 more
openaire   +1 more source